Fibromyalgia syndrome (FMS) is a chronic musculoskeletal syndrome; almost invariably, symptoms persist at 5- and 10-year follow-ups. The degree of functional impairment is similar to that seen in patients with moderate to severe rheumatoid arthritis. Anti-cyclic citrullinated peptide (anti-CCP) antibody testing is particularly useful in the diagnosis of rheumatoid arthritis, with high specificity, in the early disease process, with the ability to identify patients who are likely to have severe disease and irreversible damage. CRP is a member of the class of acute-phase reactants that its levels rise dramatically during inflammatory processes occurring in the body.
the main objective of this study is to determine the frequency of anti CCP- in patients with FM and the association of anti-CCP level with C-RP.
PATIENTS & METHODS:
This study included 60 patients with FMS according to the ACR 1990 criteria. Their age range was 20-60 years. These patients were then matched by age and sex to 30 healthy control persons with mean age 42.81 ± 2.16 years.
The mean values of ACCP antibodies concentration in serum of patients with FMS were no significant difference as compared to the level in serum of healthy controls (p>0.05), while the mean values of C-RP concentration in serum of patients with FMS were significantly increased than the level in serum of healthy control (p< 0.05).
It is clear from this study that there is no relationship between the levels of ACCP concentration and FMS while C-RP concentration in patients with FMS may be a good indicator to evaluate this disease.